SynthesisOpen heart2025
Prognostic value of CMR parametric mapping in cardiac amyloidosis: an updated systematic review and meta-analysis.
Synthesis in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Imaging Advances in Light Chain Amyloidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Prognostic parameters and detection of cardiac amyloidosis with hybridEuropean journal of nuclear medicine and molecular imaging · 2026Observational
- Cardiac MRI Across ESC Guidance in the Last Decade.Clinical cardiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac amyloidosis (CA) is the leading cause of mortality in systemic amyloidosis, highlighting the need for accurate risk assessment to guide patient management. While the diagnostic value of cardiac MR (CMR) parametric mapping is well established, its prognostic utility remains inconsistent across studies. To perform a systematic review and meta-analysis to evaluate the prognostic value of CMR parametric mapping in predicting all-cause mortality, heart failure hospitalisation and major adverse cardiovascular events in patients with CA.
methodsAn extensive search was conducted in Medline, Scopus, Embase and Web of Science databases. Eligible studies were observational studies that reported HRs for predicting predefined outcomes in patients with CA using CMR parametric mapping.
results22 studies with 3398 patients were included in this systematic review. Higher extracellular volume (ECV) values were associated with increased mortality, both as a dichotomous (HR: 2.90; 95% CI: 1.68 to 5.01) and continuous variable (HR for 1% increase: 1.08; 95% CI: 1.06 to 1.10; HR for 3% increase: 1.17; 95% CI: 1.11 to 1.22 and HR for 10% increase: 2.11; 95% CI: 1.70 to 2.62). Higher native T1 mapping values were associated with mortality as a dichotomous variable (HR: 1.33; 95% CI: 0.79 to 2.24). Native T2 mapping showed inconsistent associations with prognosis across studies.
conclusionsHigher ECV and native T1 values are associated with worse prognosis in CA, supporting their role in risk stratification. Further studies with standardised CMR protocols are needed to enhance the prognostic utility of parametric mapping in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.